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sessions, For each strategy, the associated compliance was estimated using 
survival curVes at 12, 24, and 52 weeks nnd tested statistically using the log 
rank test, A cox proportional hazards model was used to estimate the relative 
risk of compllgnca for each interval. Median time of follow up was 24 weeks 
for ST1 and 20 weeks for ST2, Clinical baselines characteristics were similar 
in both study groups. By univerlate analysis, the absonoa of previous smoking 
(p < 0,05), and the strategy evaluated (p' ~,P91) were the only predictors 
of compliance, The compliance curves were significantly different between 
both strategies (log rank tes t ,  0,001). The only Independent predictor of 
compliance was the strategy used. wlth the ST2 showing a significantly bettor 
compliance than ST1, Relative rlsk at 12 weeks RR = 2,3 [1,8. 2,9]; at 24 
weeks, RR ,. 2,95 [2,3, 3,7] and at 52 waeke, RR.  4,25 [3,2, 5,8], 
Conclusion: This study 8hews that the sfrategy with a eomblnntlon of 
multiple interventions to Increase patient commitment ~lnd Involvement In a 
variety of activities, significantly Improved the compllnnco to a rehabilitation 
program. This Is ef utmost Importance since et least three months tn a 
program 19 the minimum ttmo roqttlrod to achieve a ellnlcgl Impnot. 
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Dl~ltpldomla, Inflammation and impaired tlbrinolysis Increase the ask tOT 
coronary event9 and dnatl~, Lipid.lowering IlnS boon lound to reduce this 
risk, In ,'t randomized, do~blo-bllnd, cross-over stL~dy o! hypetlriglyceridemic 
men (n ,~ 12.394]4 yts; 6 with stable Ischomlc I~eart disease), we investigated 
whether lipid.lowQring influenced C.reactlve protein (CRP) end baseline and 
post.exer¢l,'~o llbtin0ty~ls, k morning fnst~og bleed sample was taken pro- 
end post-maximal exemlse (known to stimulate fibrlnolysis) before and after 
2-months' treatment with gomflbmzil (G: 600 mg ~ 2/d) or placebo (P), 
for measummontn of Iiplds, CRP, tissue.type plnsmlnngon activator (t.PA, 
ug/L), plasmln-antlplasmln (PAP. ug/L) and plngmtnogen activator inhibitor-1 
(PAl-l), 
Ae expected, during P. patients with IHD, vs those without, had higher 
CRP (median 4,5 va 1,1 rag/L, p = 0,006) and PAl,1 (median 86 vs 44 ug/L 
p = 0,006). Moreover, CRP and PAIq were strongly rotated (r = 0,84. p = 
0.0006). A signitlcant, similar Increase of f-PA antigen was observed tn all 
study phases after oxemiso (post-) compared with before (pro,) (p .  0,0003) 
Altar G, baseline triglyceridos (TG, mgldL) and CRP wore both significantly 
reduced, and PAP concentrations wore increased: 
TG' CRP PAP t.PA pro- t-PA post- 
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Our data suggest that TG reduction in hypertrigtyceridemic men has both 
anti-inflammatory and pro-fibrinotytic effects, This may explain, at least m 
part, the clinical benefits of lipid-lowering. 
•75• Grape Juice Inhibits Human ex Viva Platelet Aggregation While Orange and Grapefruit Juices 
do Not 
J.G. Keevil, H. Osmae, N, Mantel. JD. Felts. Cardiology Section. Unwersity 
of Wisconsin, Madison Wl. USA 
Background., Platolots contnbute to the progression of atherosclerosis and 
precipitate coroosry thrombosis leading to myocardial infarction (MI). Red 
wine and purple grape iuico (G J) contain flavonoids (Fs) with antioxidant and 
anti-platetet properties thought to reduce death from coronary artery disease 
(CAD). GJ prevents expenmental thrombos~s in monkey carotid and dog 
coronary arteries (Felts model). Orange juice (OJ} and grapefruit juice (GFJ) 
contain a different class of Fs than GJ (tlavones vs. Ilavonols). 
Methods: Ten healthy human subjects drank 5-7.5 ml/kg/day of GJ. OJ or 
GFJ daily for 7-10 days each in a three arm crossover design. Whole blood 
platelet aggregation (PA) studies were done at baseline and after each juice 
had been consumed. 
Results: Ddnking grape juice for one week inhibited the PA response to 
1 ~g/ml of collagen by 84% ~; 20% (p = 0.003). OJ and GFJ had no effect 
on PA. Platelet inhibition was still at full effect two days after stopping GJ 
consumption, but was gone in seven days. 
Conclusion: Drinking GJ daily for one week poteetly inhibited PA while 
OJ and GFJ had no effect. It appears that the flavonols in GJ. taken orally 
are more effective PA inhibitors than the flavones in OJ and GFJ. The GJ 
platelet inhibitory effect was stronger than a published standard for aspirin 
2O 
I0 
i ,  
0 
11 
Plntelet A~regation al~er ~ Week of  Fntit Juice 
Bn,~eline Grape G"rapa rrttit 
i l l  
Orango 
suggnsting that GJ, t~ken daily, may be as effective as aspirin in doe;tensing 
risk of ML 
• Hoalth's Impact on Drinking Behavior: The 
Atherosclsroals Risk In Communities (ARIC) 
Study 
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University el Misst~ssppi Medical Center, Jackson, MS, USA 
Baekgtollnd; It has been suggested ff~at the pufattvo protective effect el 
moderate alcohol consumption on cardiovascular disease is because of 
salf,selootien far drinking by those who am hoaffhier, 
Mc}thods" To test how a change in health affects drinking behavior, we 
studied 174 bl¢tck women, 2S2 black men, 2065 white women, and 1991 whdo 
mac ~rom fflO ARIC study who worn dnnkors at visit 1. who ha~d no htsfow 
at disease 0r, Voca~dtal infamtion, stroke, hyper!onslon, diabetes, ca~r ,  
or lung disease) at visit 1, and who reported dnnker status and disease 
status appmxlmatety 3 years later at visit 2. The ethnic/gender.specific, age- 
and income-adjusted odds of stopping drinking were modeled by logistic 
regression analyses for those who developed one or more of the diseases 
by visit 2 (n comparison to these who remained disease free. 
Results: In throe ethnic/gender strata, the development of disease was 
strongly associated with stopping dnnking, The odds ratios (95% CI) were as 
follows: Black men, OR = 2,9 (1.46--5,69); white men, OR = 1,6 (1.0B--237): 
white women OR = 1.8 (1,25-2.69); and black women, OR = 06  (0.21-1.68) 
Conclusion: Change in awareness of disease status is associated with a 
change in drinking behavior and should be considered when evaluating the 
cross-sectional association of alcohol and disease outcomes. 
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Total hospital cost of eorenaq., revascularization include hospital and protes- 
sional (Prof) components. Hospital cost is often determined from the hospital 
charges (UB92), reduced to cost by departmental cost to charge ratios. Prof 
costs are generally either not included or estimated tram Medicare reim- 
bursement for specific procedures, which will not cover all sen/ices provided 
during an episode of care (EOC). At Emery University there is centralized 
billing• permitting collection of all CPT codes for an EOC. CPT codes (and 
modifiers) may be related to ProI resource use by their relative value units 
(HVUs). RVUs include wurk and practice components which may be added to 
form total RVUs. RVUs for all services during an EOC are then ;.:mined and 
multiplied by the Medicare conversion factor to calculate Prot cost. Total cost 
of coronary revascularization was determined in 3,132 patients undergoing 
PTCA and 2,078 CABG in 1994 & 1995, in 1995 $: 
CABG 94 CABG 95 PTCA 94 PTCA 95 
Hospital Co~t $20.U6~ $16,333 $9.046 $6,908 
Work RVUs 47 42 20 17 
Total RVUs 109 100 52 46 
Prot Cost $4,358 $3.916 $2.071 $1.713 
Total Coz.t $24,355 $20,116 $11,072 $8.601 
All measures of resource use declined from 1994 to 1995. p ~ 0.0001. 
Ability to predict total cost from the Emery clinical database was modest 
unless length of stay (LOS) was included in the model: for CABG r2 = 0.16 
